Palatin Technologies, Inc.

31 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Jan 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Sep 1, 2027
The maintenance fee for Lactam-bridged melanocortin receptor-specific peptides (US 9,273,098) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
1 fee due Oct 28, 2027
The maintenance fee for Melanocortin receptor-specific peptides (US 10,632,171) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,795,378	Peptide compositions for treatment of sexual dysfunction In force Term ends Jan 5, 2027 · From the USPTO record	In force	Term ends Jan 5, 2027	From the USPTO record
US 7,622,440	Cyclic natriuretic peptide constructs In force Term ends Mar 30, 2027 · From the USPTO record	In force	Term ends Mar 30, 2027	From the USPTO record
US 7,709,484	Substituted Melanocortin Receptor-Specific Piperazine Compounds In force Term ends Dec 4, 2027 · High confidence	In force	Term ends Dec 4, 2027	High confidence
US 7,795,221	Linear natriuretic peptide constructs In force Term ends Jul 9, 2028 · From the USPTO record	In force	Term ends Jul 9, 2028	From the USPTO record
US 8,114,844	Linear and cyclic melanocortin receptor-specific peptidomimetics In force Term ends Apr 10, 2029 · From the USPTO record	In force	Term ends Apr 10, 2029	From the USPTO record
US 8,729,224	Melanocortin receptor-specific peptides for treatment of female sexual dysfunction In force Ends no later than Jun 8, 2029 · From the USPTO record	In force	Ends no later than Jun 8, 2029	From the USPTO record
US 8,263,608	Melanocortin receptor-specific spiro-piperidine compounds In force Term ends Sep 29, 2029 · From the USPTO record	In force	Term ends Sep 29, 2029	From the USPTO record
US 9,458,201	Melanocortin receptor-specific heptapeptides In force Ends no later than Jun 7, 2030 · From the USPTO record	In force	Ends no later than Jun 7, 2030	From the USPTO record
US 10,179,804	Melanocortin receptor-specific peptides In force Ends no later than Jun 7, 2030 · From the USPTO record	In force	Ends no later than Jun 7, 2030	From the USPTO record
US 10,632,171	Melanocortin receptor-specific peptides In force Ends no later than Jun 7, 2030 · From the USPTO record	In force	Ends no later than Jun 7, 2030	From the USPTO record

10 of 31 patents shown.

Pro members see all 31.

Pro members: see all 31 patents

Also on record, not counted in the 31: 25 lapsed for an unpaid fee · 15 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 abandoned · 15 no status recorded

List them